S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
Log in

LON:RENE - ReNeuron Group Share Price, Forecast & News

GBX 149.50
+7.00 (+4.91 %)
(As of 02/24/2020 04:00 PM ET)
Today's Range
141.10
Now: GBX 149.50
153
50-Day Range
136
MA: GBX 147.14
170.50
52-Week Range
29.50
Now: GBX 149.50
342
Volume208,179 shs
Average Volume28,700 shs
Market Capitalization£47.59 million
P/E Ratio299.00
Dividend YieldN/A
BetaN/A
ReNeuron Group plc develops and sells cell-based therapies in the United Kingdom. The company's lead therapeutic candidate is CTX stem cell therapy, which has been completed Phase II clinical trial for the treatment of patients living with chronic disability following stroke, as well as that has been completed Phase I clinical trial to treat limb ischaemia. Read More…

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-20-38198400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£95.92 million
Cash FlowGBX 52.33 per share
Book ValueGBX 191.40 per share

Profitability

Miscellaneous

Employees62
Market Cap£47.59 million
Next Earnings DateN/A
OptionableNot Optionable

Receive RENE News and Ratings via Email

Sign-up to receive the latest news and ratings for RENE and its competitors with MarketBeat's FREE daily newsletter.


ReNeuron Group (LON:RENE) Frequently Asked Questions

What is ReNeuron Group's stock symbol?

ReNeuron Group trades on the London Stock Exchange (LON) under the ticker symbol "RENE."

How were ReNeuron Group's earnings last quarter?

ReNeuron Group Plc (LON:RENE) announced its earnings results on Friday, December, 6th. The company reported ($12.30) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($16.30) by $4.00. View ReNeuron Group's Earnings History.

Has ReNeuron Group been receiving favorable news coverage?

Press coverage about RENE stock has trended somewhat positive on Monday, InfoTrie Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. ReNeuron Group earned a coverage optimism score of 2.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for ReNeuron Group.

Who are some of ReNeuron Group's key competitors?

What other stocks do shareholders of ReNeuron Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ReNeuron Group investors own include International Road Dynamics (IRD), Sareum (SAR), ValiRx (VAL), Independent Oil & Gas (IOG), Dignity (DTY), Tri-star Resources (TSTR), Sirius Minerals (SXX), Collagen Solutions (COS), RenovaCare (RCAR) and ReNeuron Group (RNUGF).

Who are ReNeuron Group's key executives?

ReNeuron Group's management team includes the folowing people:
  • Mr. Olav Hellebø, CEO & Director (Age 54)
  • Mr. Michael E. Hunt, CFO, Sec. & Exec. Director (Age 56)
  • Dr. John David Sinden BA, MA, Ph.D., Founder & Chief Scientific Officer (Age 68)
  • Dr. Randolph Corteling, Head of Research
  • Mr. Shaun Stapleton BSc (Hons) MTOPRA, Head of Regulatory Affairs

How do I buy shares of ReNeuron Group?

Shares of RENE and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is ReNeuron Group's stock price today?

One share of RENE stock can currently be purchased for approximately GBX 149.50.

How big of a company is ReNeuron Group?

ReNeuron Group has a market capitalization of £47.59 million and generates £95.92 million in revenue each year. ReNeuron Group employs 62 workers across the globe.View Additional Information About ReNeuron Group.

What is ReNeuron Group's official website?

The official website for ReNeuron Group is http://www.reneuron.com/.

How can I contact ReNeuron Group?

ReNeuron Group's mailing address is Pencoed Business Park, BRIDGEND, CF35 5HY, United Kingdom. The company can be reached via phone at +44-20-38198400.


MarketBeat Community Rating for ReNeuron Group (LON RENE)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  186 (Vote Outperform)
Underperform Votes:  120 (Vote Underperform)
Total Votes:  306
MarketBeat's community ratings are surveys of what our community members think about ReNeuron Group and other stocks. Vote "Outperform" if you believe RENE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RENE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/24/2020 by MarketBeat.com Staff

Featured Article: Why do commodities matter?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel